Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01110382 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections
A Phase 3 study, sponsored by Janssen Research & Development.
- Terminated
- Registry status
- Phase 3
- Development phase
- 41
- Enrollment target
NCT01110382 is a Phase 3 study that was terminated before completion, run by Janssen Research & Development. The registered enrollment target is 41 participants.
The verdict
NCT01110382, a Phase 3 study, was terminated before completion, sponsored by Janssen Research & Development.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
Interventions
- DRUG Meropenem
- DRUG Doripenem
- DRUG Doripenem placebo
- DRUG Amoxicillin/clavulanate potassium
- DRUG Meropenem placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2010-12 |
| Est. Completion | 2013-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01110382
The ClinicalTrials.gov registry entry for NCT01110382 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Meropenem is the first listed.
NCT01110382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01110382 about?
NCT01110382 is a clinical study titled "A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections". The purpose of the study is to evaluate the safety and tolerability of doripenem compared with meropenem in children hospitalized with complicated intra-abdominal infections.
What is the current status of trial NCT01110382?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 41 participants. The study started on 2010-12. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01110382?
The interventions under investigation include: Meropenem (DRUG), Doripenem (DRUG), Doripenem placebo (DRUG), Amoxicillin/clavulanate potassium (DRUG), Meropenem placebo (DRUG).
Who is sponsoring clinical trial NCT01110382?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.